The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 20, 2021

Filed:

Oct. 20, 2017
Applicant:

3dt Holdings, Llc, San Diego, CA (US);

Inventors:

Ghassan S. Kassab, La Jolla, CA (US);

Carlos A. Labarrere, San Diego, CA (US);

Assignee:

3DT Holdings, LLC, San Diego, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); G01N 33/86 (2006.01); A61K 39/00 (2006.01); A61K 31/14 (2006.01); A61K 39/395 (2006.01); C12N 5/0786 (2010.01); A61K 35/12 (2015.01); C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0013 (2013.01); A61K 39/001 (2013.01); G01N 33/68 (2013.01); G01N 33/686 (2013.01); G01N 33/6854 (2013.01); G01N 33/86 (2013.01); A61K 31/14 (2013.01); A61K 39/0012 (2013.01); A61K 39/39566 (2013.01); A61K 2035/124 (2013.01); C07K 16/00 (2013.01); C12N 5/0645 (2013.01); G01N 33/6893 (2013.01); G01N 2333/4712 (2013.01); G01N 2333/70525 (2013.01); G01N 2333/745 (2013.01); G01N 2333/968 (2013.01); G01N 2800/245 (2013.01); G01N 2800/50 (2013.01);
Abstract

Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy.


Find Patent Forward Citations

Loading…